Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis

作者：Liu, Nan^*; Tai, Sheng; Ding, Boxiao; Thor, Ryan K.; Bhuta, Sunita; Sun, Yin; Huang, Jiaoti

来源：Endocrine-Related Cancer, 2012, 19(5): 711-723.

DOI：10.1530/ERC-12-0150

• MTOR INHIBITOR EVEROLIMUS
• BREAST-CANCER
• GROWTH ARREST
• UP-REGULATION
• MOUSE MODEL
• COMBINATION
• BCL-2
• CARCINOMA
• MECHANISM
• PATHWAY

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway plays a key role in the tumorigenesis of a variety of human cancers including ovarian cancer. However, inhibitors of this pathway such as Rad001 have not shown therapeutic efficacy as a single agent for this cancer. Arsenic trioxide (ATO) induces an autophagic pathway in ovarian carcinoma cells. We found that ATO can synergize with Rad001 to induce cytotoxicity of ovarian cancer cells. Moreover, we identified synergistic induction of autophagy and apoptosis as the likely underlying mechanism that is responsible for the enhanced cytotoxicity. The enhanced cytotoxicity is accompanied by decreased p-AKT levels as well as upregulation of ATG5-ATG12 conjugate and LC3-2, hallmarks of autophagy. Rad001 and ATO can also synergistically inhibit tumors in a xenograft animal model of ovarian cancer. These results thus identify and validate a novel mechanism to enhance and expand the existing targeted therapeutic agent to treat human ovarian cancer. Endocrine-Related Cancer (2012) 19 711-723

• 出版日期2012-10
• 单位南方医科大学; 安徽医科大学